Blueprint Medicines stock soars 18% on positive 2025 growth outlook and promising study results

From Zacks Investment Research: 2025-01-14 11:20:12

Shares of Blueprint Medicines (BPMC) surged 18.2% after announcing its 2025 corporate outlook, projecting a peak revenue opportunity of $4 billion for its SM franchise, with Ayvakit expected to achieve $2 billion in annual revenues by 2030. The company also reported upbeat data from its Phase I BLU-808 study, showing promising results in mast cell-driven diseases. Blueprint is further developing elenestinib (BLU-263) and CDK2 and CDK4 targeted protein degraders for breast cancer and solid tumors. The company holds a Zacks Rank #2 (Buy) and is actively exploring partnerships to expand its CDK franchise. Other top-ranked stocks in the sector include Castle Biosciences (CSTL), CytomX Therapeutics (CTMX), and Halozyme Therapeutics (HALO). Castle Biosciences has lost 21.9% in the past three months, while CytomX Therapeutics has lost 20.8% during the same timeframe, and Halozyme Therapeutics has gained 0.6% over three months. Castle Biosciences and CytomX Therapeutics sport a Zacks Rank #1 (Strong Buy), while Halozyme Therapeutics carries a Zacks Rank #2. Castle Biosciences has delivered an average earnings surprise of 172.72%, while CytomX Therapeutics has an average surprise of 115.70%, and Halozyme Therapeutics has an average surprise of 14.86% in their earnings performance.



Read more at Zacks Investment Research: Blueprint Stock Soars 18% on Encouraging 2025 Growth Strategy – January 14, 2025